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Abbreviations used: 28 
ASMC: Airway Smooth Muscle Cells 29 
CS: Corticosteroids 30 
DMP: Differentially Methylated Position 31 
FCS: Foetal calf serum 32 
GPCR: G-protein-coupled receptor 33 
HS: healthy subject 34 
NSA: non-severe asthma 35 
SA: severe asthma  36 
WGCNA: Weighted Gene Correlation Network Analysis 37 
miRNA: microRNA  38 
Asthma is a chronic airway inflammatory disorder characterized by airway 39 
hyperresponsiveness, inflammation and remodelling, including ASMC hyperplasia and 40 
subepithelial airway fibrosis [1, 2]. Airway smooth muscle cells (ASMCs) from severe 41 
asthmatics are hyperproliferative, release more pro-inflammatory cytokines and are CS-42 
insensitive compared to healthy individuals and non-severe asthma patients [3, 4]. Genetic and 43 
epigenetic processes such as miRNA expression and DNA methylation have been implicated 44 
in asthma pathogenesis [5]. Indeed, DNA methylation is altered in asthmatic blood cells [5] 45 
and may be a biomarker of atopy [6]. 46 
 47 
We hypothesised that genome-wide analysis of DNA methylation associated with altered 48 
mRNA and miRNA expression will reveal insights into pathways driving severe asthma 49 
particularly in ASMCs whose function is abnormal in disease. We analysed the 50 
interconnections and functional relevance of differences in DNA methylation status and the 51 
expression of mRNAs and miRNAs in ASMCs cultured from bronchial biopsies obtained from 52 
5 healthy subjects (HS), 5 non-severe asthmatics (NSA) and 5 severe asthmatics (SA), at 53 
baseline and following stimulation with 2.5% FCS and TGF-β (1 ng/ml)[3, 4]. This stimulus is 54 
known to induce ASMC proliferation and enhance the release of inflammatory mediators in a 55 
severity-dependent manner [3, 4]. SA and NSA were defined as previously described [1, 2]. 56 
HS had no previous history of asthma and PC20 >16 mg/ml. Full patient demographics are 57 
shown in Table 1.  58 
 59 
DNA methylation analysis using the Illumina 450K array (Infinium HumanMethylation450K 60 
v1.2, San Diego, CA) identified 12,383 differentially methylated positions (DMPs) (defined 61 
by >20% mean methylation difference) which clustered by clinical designation (Fig. 1a). 62 
Analysis of DMPs between groups revealed 15 hub sites (Fig. 1b) that, apart from TRPV1, are 63 
associated with novel asthma genes linked to important processes/pathways implicated in 64 
asthma pathophysiology including inflammatory, metabolic and proliferative pathways in 65 
ASMCs from SA. 66 
 67 
Pathway analysis using g:Profiler [7] indicated that the genes associated with DMPs in HS 68 
versus NSA at baseline were involved in the regulation of cell proliferation and apoptosis 69 
(Hippo signalling pathway) and axon guidance whilst differences between SA and controls 70 
were associated with ASMC contraction (calcium signalling pathway), proliferation (cancer-71 
related pathways) and the endocytosis pathway (Fig. 1c). Stimulation of HS ASMCs activated 72 
pathways similar to those seen in the NSA and SA cells (hippo pathway and endocytosis). This 73 
suggests that ASMCs from NSA and SA retain an epigenetic profile linked to cell proliferation 74 
and asthma despite being in culture for several passages. Stimulated NSA ASMCs increased 75 
DMPs linked with repression of innate immune responses (Epstein-barr virus infection) whilst 76 
in SA cells, the Notch signalling pathway was most significantly activated. This data highlights 77 
the importance of altered innate immunity and proliferative signalling by Notch in severe 78 
asthma ASMCs. 79 
 80 
We used a different approach to examine the importance of severity-associated DMPs namely 81 
weighted gene co-expression analysis (WGCNA) [8] and Bumphunter analysis [9]. We 82 
identified 5/19 modules as being significantly correlated with disease severity (Fig. 1d). 83 
Filtering of these phenotype–associated CpG sites for significance and connectivity gave 15 84 
phenotype DMPs that were more enriched in genomic CpG shores or regions immediately 85 
flanking CpG islands and confirmed the importance of the previously identified DBX2, ACP6 86 
and KCNJ11 as hub DMPs. These genes are associated with altered fatty acid metabolism and 87 
proliferation (ACP6), GPCR signalling in metabolic syndrome (KCNJ11) and neuronal 88 
patterning (DBX2). 89 
This analysis also confirmed the previously- reported decrease in baseline PDE4D 90 
(Phosphodiesterase 4D) promoter region methylation in asthma that modulated asthmatic 91 
ASMC proliferation [10]. However, this effect was reversed when cells were stimulated with 92 
FCS/TGF-β highlighting that ASMC DNA methylation status is labile upon cell activation to 93 
induce functional consequences. Pathway analysis of phenotype-associated DMPs confirmed 94 
the importance of the Hippo signalling, axon guidance and endocytosis pathways but also 95 
delineated novel pathways including endocannabinoid signalling, which is typically present in 96 
the brain [11], and of viral induction of tumours [12]. Further investigation of the role of these 97 
pathways in SA is required. 98 
DNA methylation not only regulates gene expression but also that of miRNAs. Altered 99 
expression of miRNAs regulates many physiological processes including inflammation and 100 
remodelling and has been implicated in asthma [3]. We examined whether the DMPs described 101 
here may also control miRNA expression particularly as one of the 15 hub DMPs is associated 102 
with miR-548a-3 (Fig. 1b). We found altered expression of numerous miRNAs (measured by 103 
RT-PCR as previously described [3, 13, 14]) whose loci were linked with DMPs in asthmatic 104 
ASMC at baseline and following stimulation. 113 DMPs associated with miRNA loci were 105 
seen comparing HS and NSA patients; 104 when comparing HS and SA samples and 120 when 106 
comparing NSA and SA ASMCs (Fig. 1e). The miRNAs associated with the highest and lowest 107 
methylated CpGs in the HS ASMCs being MIR137 and MIR372 respectively, MIR548Q and 108 
MIR575 in the NSA samples, and MIR1265 and MIR1266 in ASMCs from SA. MIR137, 109 
MIR372 and MIR575 have been reported to be aberrantly expressed in both ASMCs [13] and 110 
asthmatic lung biopsies [14]. However, we show for the first time that miR-1265 and miR-1266 111 
are overexpressed in SA ASMCs. 112 
Stimulation with FCS/TGF-β had a greater effect on DMPs in SA cells with significantly 113 
altered DMPs seen at 10 miRNAs in HS ASMCs, 18 in the NSA and 50 in SA ASMCs at FDR 114 
(Fig. 1f). The highest and lowest methylated positions, respectively, in HS ASMCs were 115 
associated with MIR218-1 and MIR548F5, MIR613 and MIR125B1 in NSA samples, and with 116 
MIR663 and MIR320D1 in the ASMCs from SA (Fig. 1f). Using RT-PCR, we confirmed the 117 
expected change in expression of the mature miRNAs correlating with the respective increase 118 
or decrease in methylation status. The most highly-expressed miRNA was miR-320d-1 in the 119 
SA ASMC, confirming our previous reports in both ASMCs [13] and asthmatic lung biopsies 120 
[14] (Fig. 1f). In summary, our data suggests that regulation of proliferative/apoptotic pathways 121 
are abnormal in ASMC from SA patients and that this may be under the control of dysregulated 122 
metabolic processes particularly relating to fatty acid metabolism. 123 
 124 
Overall, there was ~80% overlap of DNA methylation profiles reported here and with gene 125 
expression profiles from HS and, NSA and SA primary ASMCs, as previously published [5, 126 
13, 14]. This not only confirms our focussed analysis at the mRNA level but also suggests that 127 
factors such as diet and lifestyle, known to affect DNA methylation status [15], are unlikely to 128 
cause a major bias here. Larger focussed studies will be required to address these issues.  129 
 130 
We confirm that distinct patterns of DNA methylation are associated with asthma per se and 131 
also with disease severity. These methylation changes, in turn, are associated with changes in 132 
gene expression and miRNA expression which may influence ASMC function. Indeed, we 133 
describe a new mechanism underlying ASMC dysfunction in severe asthma and provide a 134 
rationale for delineating the potential therapeutic action of demethylating agents (i.e. adjuvant 135 
treatment). We also highlight the potential role of novel pathways such as endocannabinoid 136 
signalling in mediating ASMC function in SA. Therefore, this study not only extends our 137 
understanding of the multi-layered or integrated nature of the regulatory mechanisms that 138 
control SA ASMC phenotype, but it should stimulate more work on the functional regulation 139 
of ASMC function in SA with the potential for newer more effective therapies aimed at not 140 
only relieving the increased airway tone but also the hyperproliferative and proinflammatory 141 
ASMC of severe asthma. 142 
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Tables 173 
Table 1: Patient Demographics 174 




n 5 5 5 
Age (yrs.) 36.4 ± 12.72 42.1 ± 16.06 40.9 ± 11 
Sex (♂ - ♀) 3 – 2 2 – 3 0 - 5 
Duration of asthma 
(yrs.) 
N/A 21.2 ± 15.32 25.56 ± 13.24 
Inhaled corticosteroid 
dose  0 480 ± 582.71 1688.89 ± 176.38 
(μg BDP equivalent) 
Atopy (n) 0 3 5 
Receiving oral 
corticosteroids 
0 0 5 
FEV1 (L) 4.02 ± 0.48 2.7 ± 0.82 2.7 ± 0.77 
FEV1 (% Predicted) 104.23 ± 7.28 84.48 ± 18.34 81.42 ± 14.82 
FEV1/FVC (%) 78.89 ± 5.98 73.98 ± 9.67 69.62 ± 9.31 
PC20 (mg/ml) > 16 0.75 ± 9.31 Not performed 
 175 
 176 
Figure Legend 177 
Figure 1: DNA methylation sites and miRNA regulation in severe asthma airway smooth 178 
muscle cells. 179 
[A] Heatmap showing global methylation pattern of airway smooth muscle. Unsupervised 180 
hierarchical clustering of 12,383 differentially methylated DNA sites. Red represents high 181 
methylation and green represents low methylation. [B] Change in RNA expression of the 15 182 
‘hub’ genes, as measured by RT-PCR. [C] Pathway analysis of genes associated with 183 
differentially methylated positions (DMPs). [D] The genomic location of 3 the hub DMPs 184 
suggested by both WGCNA and bumphunter analysis, are shown. The KCNJ11 DMP sits in 185 
both the CpG island and promoter regions, whereas ACP6 and DBX2 sit in both CpG shore and 186 
promoter regions. [E] Venn diagrams showing Inter-group comparison of differential 187 
methylation sites associated with miRNAs at baseline. [F] Graphical representation of the 188 
numbers of differentially expressed miRNAs sites in healthy, non-severe and severe asthmatic 189 
ASM following stimulation with FCS (2.5%) and TGF-β (1ng/ml), both at the methylation 190 
level and miRNA level.  191 
 192 
  193 
References 194 
1. Chung KF, Wenzel SE, Brozek JL et al. International ERS/ATS guidelines on 195 
definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43(2): 343-196 
373. 197 
2. Reddel HK, Bateman ED, Becker A et al. A summary of the new GINA strategy: a 198 
roadmap to asthma control. Eur Respir J. 2015 Sep;46(3):622-39.  199 
3. Perry MM, Baker JE, Gibeon DS, Adcock IM, Chung KF. Airway smooth muscle 200 
hyperproliferation Is regulated by microRNA-221 in severe asthma. Am J Respir Cell 201 
Mol Biol 2013; 50(1): 7-17. 202 
4. Chang PJ, Bhavsar PK, Michaeloudes C, Khorasani N, Chung KF. Corticosteroid 203 
insensitivity of chemokine expression in airway smooth muscle of patients with severe 204 
asthma. J Allergy Clin Immunol 2012; 130(4): 877-885. 205 
5. Potaczek DP, Harb H, Michel S et al. Epigenetics and allergy: from basic mechanisms 206 
to clinical applications. Epigenomics. 2017; 9(4): 539-571.  207 
6. Liang L, Willis-Owen SA, Laprise C et al. An epigenome-wide association study of 208 
total serum immunoglobulin E concentration. Nature. 2015; 520(7549): 670-4.  209 
7. Reimand J, Arak T, Vilo J. g:Profiler--a web server for functional interpretation of gene 210 
lists (2011 update). Nucleic Acids Res 39 (Web Server issue), W307-W315 (2011). 211 
8. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network 212 
analysis. BMC Bioinformatics. 2008; 9: 559. 213 
9. Jaffe AE, Murakami P, Lee H et al. Bump hunting to identify differentially methylated 214 
regions in epigenetic epidemiology studies. Int J Epidemiol. 2012; 41(1): 200-209. 215 
10. Lin AH, Shang Y, Mitzner W, Sham JS, Tang WY. Aberrant DNA Methylation of 216 
Phosphodiesterase 4D: Effect on Airway Smooth Muscle Cell Phenotypes. Am J Respir 217 
Cell Mol Biol 2016; 54(2): 241-9.  218 
11. Di Marzo V, Stella N, Zimmer A. Endocannabinoid signalling and the deteriorating 219 
brain. Nat Rev Neurosci. 2015; 16(1): 30-42. 220 
12. Pierangeli A, Antonelli G, Gentile G. Immunodeficiency-associated viral oncogenesis. 221 
Clin.Microbiol.Infect. 2015; 21(11): 975-83. 222 
13. Perry M, Tsitsiou E, Austin P et al. Role of non-coding RNAs in maintaining primary 223 
airway smooth muscle cells. Respiratory Research 2014; 15(1): 58. 224 
14. Williams AE, Larner-Svensson H, Perry MM et al. MicroRNA Expression Profiling in 225 
Mild Asthmatic Human Airways and Effect of Corticosteroid Therapy. PLoS ONE 226 
2009; 4(6): e5889. 227 
15. Lim U, Song MA. Dietary and lifestyle factors of DNA methylation. Methods Mol Biol. 228 
2012;863:359-76.  229 
